Navigation Links
Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium

REDWOOD CITY, Calif., Dec. 7 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from eight studies of the company's Oncotype DX(R) breast cancer test are scheduled to be presented at the 30th Annual San Antonio Breast Cancer Symposium, taking place December 13-16, 2007. Oncotype DX is a multi-gene expression test that physicians use to predict the likelihood of recurrence and the likelihood of chemotherapy benefit for a large portion of early-stage breast cancer patients.

Following are details for each embargoed session (all times are Central Standard Time):

Thursday, Dec. 13, 2007, 9:15 to 9:30 a.m.

Abstract #10

Late-Breaking oral presentation: "Prognostic and predictive value of the

21-gene Recurrence Score assay in postmenopausal, node-positive, ER

positive breast cancer.

"Presenter: Kathy S. Albain, M.D.

Thursday, Dec. 13, 2007, 5 to 7 p.m.

Abstract #1043

Poster presentation: Recurrence Score by Oncotype DX evaluated on the

primary breast tumor predicts the 2-year survival after first relapse.

Presenter: Giampaolo Bianchini, M.D.

Abstract #1092

Poster presentation: "Prospective multi-center study of the impact of the

21-gene Recurrence Score assay on patient satisfaction, anxiety and

decisional conflict for adjuvant breast cancer treatment


"Presenter: Patricia B. Mumby, Ph.D.

Friday, Dec. 14, 7 to 9 a.m.

Abstract #2061

Poster presentation: "A retrospective analysis of the impact of Oncotype

DX low Recurrence Score results on treatment decisions in a single

academic breast cancer center.

"Presenter: Hongmei Liang, M.D., Ph.D.

Friday, Dec. 14, 5 to 7 p.m.

Abstract #3028

Poster presentation: "Gene expression by standardized quantitative RT-PCR

in the special histologic subtypes of estrogen receptor positive invasive

breast cancer.

"Presenter: Frederick L. Baehner, M.D.

Abstract #3082

Poster presentation: "Evaluation of practice patterns in the treatment of

node-negative, hormone-receptor positive breast cancer patients with the

use of the Oncotype DX assay at the University of Pennsylvania.

"Presenter: Christopher Erb, M.D., Ph.D.

Saturday, Dec. 15, 4 to 4:15 p.m.

Abstract #63

Oral presentation: "Prognostic utility of the 21-gene assay

compared with Adjuvant! in hormone receptor (HR) positive operable breast

cancer with 0-3 positive axillary nodes treated with adjuvant

chemohormonal therapy (CHT): an analysis of intergroup trial


"Presenter: Lori J. Goldstein, M.D.

Saturday, Dec. 15, 5 to 7 p.m.

Abstract #5029

Poster presentation: "Estrogen receptor and breast cancer survival in a

Kaiser Permanente population-based study: comparison of quantitative

reverse transcriptase polymerase chain reaction and


"Presenter: Laurel A. Habel, M.D.

About Oncotype DX(R)

Oncotype DX is the first diagnostic multi-gene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of breast cancer recurrence, the likelihood of breast cancer survival and the likelihood of chemotherapy benefit. Oncotype DX has been extensively evaluated in multiple independent studies involving more than 3,300 breast cancer patients, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. To date, nearly 7,000 physicians have ordered more than 40,000 tests, and health plans covering over 50 percent of U.S. insured lives provide reimbursement for Oncotype DX through contracts, agreements and policy decisions. The American Society of Clinical Oncologists (ASCO) recommends the use of Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. For more information about Oncotype DX, please visit

About Genomic Health

Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test service, Oncotype DX(TM), which has been shown to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit in early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit

NOTE: Genomic Health, the Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

SOURCE Genomic Health, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Personalized Medicine - The Genomic Revolution in Cardiac Care
4. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
5. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
6. Microarray Sequence Capture Speeds Large-Scale Resequencing of Targeted Genomic Regions
7. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
8. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
9. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
10. Tone Deafness Explained, from the Harvard Health Letter
11. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
Post Your Comments:
(Date:11/24/2015)... The hope of bearing a ... IVF cycles. After failure of over 15 IVF cycles, ... all hopes that she would be able to conceive ever. But finally optimism prevailed as ... failure of over 15 IVF cycles. ... take one last attempt with Gaudium IVF Center in ...
(Date:11/24/2015)... CARLOS, Calif. , Nov. 24, 2015 ... a leader in non-invasive genetic testing and ... announced that it will present at the ... in New York on Wednesday, December 2, 2015 at 1:00 p.m. ET.  Matthew ... the Company,s financial results, business activities and ...
(Date:11/24/2015)... 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the ... that the first patient has been enrolled in ESSA,s ... for metastatic castration-resistant prostate cancer ("mCRPC"). ... --> the United States and ... clinical trial, ESSA intends to demonstrate the safety, tolerability, ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... 24, 2015 , ... In response to recent news highlighting Oxycodone fraud, Novus ... in the United States grew 400 percent between 1999 and 2010, far more than ... 37 percent of all fatal drug overdoses. (1) , While oxycodone and the extended ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Serenity Point ... a series of recent video interviews with some of the staff members at their ... the residential treatment facility, as well as some of the things that make their ...
(Date:11/24/2015)... ... 2015 , ... Chiropractic student Katie Benson received a $2,500 ... Park, Kansas. Benson, a fifth-trimester student in the university’s College of Chiropractic, accepted ... 16. , “Katie is very excited and greatly appreciative to receive the Standard ...
(Date:11/24/2015)... ... November 24, 2015 , ... Autism Speaks, the world’s leading autism science and ... media and the generosity of people around the world. On December 1, supporters can ... give – and share the personal stories behind those gifts. , Just as ...
(Date:11/24/2015)... ... November 24, 2015 , ... World ... Fragrance by Marcelle, a cosmetic invention which offers a combination of natural essential ... in the US is worth $3 billion annually," says Scott Cooper, CEO and ...
Breaking Medicine News(10 mins):